A Chemical Linker for Attaching Drugs to Antibodies
This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment.
Original patent title: “Covalent linkers in antibody-drug conjugates and methods of making and using the same”
This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment. Granted to Rc Biotechnologies in 2020 with 3 claims and 1 forward citation, and it is expected to expire in 2038.
Coverage
What does this patent actually cover?
This patent provides novel chemical compositions for a "linker-active agent." This agent has two main parts: a "linker" and an "active agent." The linker is specifically designed with a structure (Formula I) that can chemically bond, or "covalently couple," to specific chemical groups called "free thiols" found on an antibody. The "active agent" (Q) is then attached to this linker, and it can be a drug, like a "tubulin binder" or "DNA alkylator," or even a "visualization agent." For example, this technology could be used to attach a chemotherapy drug to an antibody that specifically recognizes cancer cells, allowing the drug to be delivered directly to the tumor.
The gap
What does this patent NOT cover?
- Linkers that do not attach to "free thiols" on an antibody, such as those that attach to lysine residues.
- Linkers that do not conform to the specific chemical structure of Formula I as described in claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1.
- Linkers that use different reactive groups for attachment to the antibody than those listed for R1 and R2 (e.g., maleimide, halogen, alkanal).
- Linker-active agents that are identical to the specific chemical structure explicitly excluded by the provision in claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1.
- Linkers that are not designed to carry an "active agent" such as a drug, enzyme inhibitor, or visualization agent.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever bit lies in the precise chemical design of the linker (Formula I) and its reactive groups (R1, R2). This specific architecture allows for stable and controlled covalent attachment to an antibody's thiol groups while also providing a way to carry and potentially release a potent active agent, which is critical for the effectiveness and safety of targeted drug delivery.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Kadcyla (trastuzumab emtansine)
Adcetris (brentuximab vedotin)
Enhertu (trastuzumab deruxtecan)
Trodelvy (sacituzumab govitecan)
Padcev (enfortumab vedotin)
Why it matters
The bigger picture
This patent contributes to the field of Antibody-Drug Conjugates (ADCs), which are a rapidly growing class of targeted cancer therapies. By providing specific, stable linker chemistries, it helps ensure that the drug stays attached to the antibody until it reaches the target cells, minimizing damage to healthy tissues. This precision is crucial for developing safer and more effective treatments for diseases like cancer.
Filed
February 14, 2018
Granted
September 15, 2020
Market context
Who's building on this
Companies in this space
Many major pharmaceutical companies and biotechnology firms are actively developing and commercializing Antibody-Drug Conjugates (ADCs). Companies like Genentech (Roche), AstraZeneca, Seagen (now part of Pfizer), Takeda, and Gilead Sciences are key players in this space, constantly seeking improved linker technologies. Rc Biotechnologies Inc., the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is also active in this area.
Market impact
This patent's technology contributes to the broader field of Antibody-Drug Conjugates (ADCs), which has created a significant new category of targeted cancer therapies. ADCs offer a promising alternative to traditional chemotherapy by delivering potent drugs directly to cancer cells, potentially reducing systemic side effects. This has spurred substantial investment in oncology drug development and fostered intense competition among pharmaceutical companies to develop novel and more effective ADC platforms.
Claim 1 — Plain English
What this patent covers
This patent provides novel chemical compositions for a "linker-active agent." This agent has two main parts: a "linker" and an "active agent." The linker is specifically designed with a structure (Formula I) that can chemically bond, or "covalently couple," to specific chemical groups called "free thiols" found on an antibody. The "active agent" (Q) is then attached to this linker, and it can be a drug, like a "tubulin binder" or "DNA alkylator," or even a "visualization agent." For example, this technology could be used to attach a chemotherapy drug to an antibody that specifically recognizes cancer cells, allowing the drug to be delivered directly to the tumor.
The clever bit
The clever bit lies in the precise chemical design of the linker (Formula I) and its reactive groups (R1, R2). This specific architecture allows for stable and controlled covalent attachment to an antibody's thiol groups while also providing a way to carry and potentially release a potent active agent, which is critical for the effectiveness and safety of targeted drug delivery.
What it does not cover
- Linkers that do not attach to "free thiols" on an antibody, such as those that attach to lysine residues.
- Linkers that do not conform to the specific chemical structure of Formula I as described in claim 1.
- Linkers that use different reactive groups for attachment to the antibody than those listed for R1 and R2 (e.g., maleimide, halogen, alkanal).
- Linker-active agents that are identical to the specific chemical structure explicitly excluded by the provision in claim 1.
- Linkers that are not designed to carry an "active agent" such as a drug, enzyme inhibitor, or visualization agent.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
Patent enters public domain
PatentBrief Score
Impact Score
Limited data
Citation count
6/40
Early citations
Claim breadth
2/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
10/20
Granted 5–10 years ago
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$72K – $230K
Midpoint $144K · 11.2 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
3 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
ZHANG, L., Ye, H., Fang, J., & Huang, C. (2020). A Chemical Linker for Attaching Drugs to Antibodies (U.S. Patent No. 10,772,965). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/10772965/covalent-linkers-in-antibody-drug-conjugates-and-methods-of-making-and-using-the
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US10772965"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 12121527 · 2024 · NBE Therapeutics AG
Making Cancer-Fighting Antibody Drugs Safer with Precise Attachment
US 20230364252 · Immunogen
Making Antibody Drug Conjugate Medicines Consistent Across Batches
US 20210301031 · Mersana Therapeutics
Targeted Cancer Drugs Using Antibodies and Polymer Scaffolds
US 5455030 · 1995 · Enzon Labs Inc
How to Build Smaller, Synthetic Antibody-Like Molecules for Medicine
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does A Chemical Linker for Attaching Drugs to Antibodies cover?
This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment.
Who owns patent US 10772965?
Rc Biotechnologies owns this patent, granted in 2020.
When does this patent expire?
This patent is expected to expire on February 14, 2038, when the invention enters the public domain.
What is patent US 10772965 cited by?
This patent has been cited by 1 later patents that build on its ideas.
What problem does this patent solve?
This patent contributes to the field of Antibody-Drug Conjugates (ADCs), which are a rapidly growing class of targeted cancer therapies. By providing specific, stable linker chemistries, it helps ensure that the drug stays attached to the antibody until it reaches the target cells, minimizing damage to healthy tissues. This precision is crucial for developing safer and more effective treatments for diseases like cancer.
What does this patent NOT cover?
Linkers that do not attach to "free thiols" on an antibody, such as those that attach to lysine residues.
Patent monitoring






